Wake Forest Institute for Regenerative Medicine

Second All-Private Astronaut Mission to the International Space Station Also Brings Compelling Science and Technology Demonstrations

Retrieved on: 
Thursday, May 11, 2023

KENNEDY SPACE CENTER, Fla., May 11, 2023 /PRNewswire/ -- The second launch of an all-private astronaut mission to the International Space Station (ISS) by Axiom Space builds on the new era of privatized utilization of the orbiting laboratory.

Key Points: 
  • KENNEDY SPACE CENTER, Fla., May 11, 2023 /PRNewswire/ -- The second launch of an all-private astronaut mission to the International Space Station (ISS) by Axiom Space builds on the new era of privatized utilization of the orbiting laboratory.
  • Axiom Mission 2 (Ax-2) will send four private astronauts to the space station.
  • These investigations span diverse disciplines, from life sciences to biomanufacturing, materials science, technology demonstrations, and education projects.
  • Alqarni and Barnawi are the first two representatives from the Kingdom of Saudi Arabia slated to launch on a mission to the space station.

Scientists Create Most Powerful, Accurate Tool Yet to Research Deadliest Blood Cancer

Retrieved on: 
Monday, April 17, 2023

NEW YORK, April 17, 2023 /PRNewswire-PRWeb/ -- Tisch Cancer Center scientists have developed unique models of the deadliest blood cancer, acute myeloid leukemia (AML), creating a transformative resource to study this cancer and eventually its drug response and drug resistance. The models were described in a late-breaking abstract at the annual meeting of the American Association of Cancer Research and simultaneously published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.

Key Points: 
  • Tisch Cancer Center scientists have developed unique models of the deadliest blood cancer, acute myeloid leukemia (AML), creating a transformative resource to study this cancer and eventually its drug response and drug resistance.
  • The models were described in a late-breaking abstract at the annual meeting of the American Association of Cancer Research and simultaneously published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.
  • NEW YORK, April 17, 2023 /PRNewswire-PRWeb/ -- Tisch Cancer Center scientists have developed unique models of the deadliest blood cancer, acute myeloid leukemia (AML), creating a transformative resource to study this cancer and eventually its drug response and drug resistance.
  • The models were described in a late-breaking abstract at the annual meeting of the American Association of Cancer Research and simultaneously published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.

Epredia and Aiforia Join RegenMed Hub Innovation Accelerator, Expanding PHC Group Presence in Regenerative Medicine

Retrieved on: 
Wednesday, January 18, 2023

PHC Group, a global healthcare company and leader in diagnostics and life sciences, will expand its presence in regenerative medicine by joining the RegeneratOR Innovation Accelerator.

Key Points: 
  • PHC Group, a global healthcare company and leader in diagnostics and life sciences, will expand its presence in regenerative medicine by joining the RegeneratOR Innovation Accelerator.
  • The RegenMed Development Organization (ReMDO) and the Wake Forest Institute for Regenerative Medicine (WFIRM), two organizations accelerating the discovery and translation of regenerative medicine therapies located in the Innovation Quarter, made the announcement today at a special event.
  • The Innovation Accelerator, another ReMDO program, was created to provide space and support for companies with new or emerging regenerative medicine technologies.
  • The presence of PHC Group, including Epredia, and Aiforia’s advanced technological support at the Innovation Accelerator will also pave the way for RegeneratOR’s newest program – the RegenMed Clinical Trials Catalyst.

Methuselah Foundation Launches $1 Million Competition to Stimulate Development of Animal-Free Precision Medicine

Retrieved on: 
Tuesday, September 20, 2022

DUBLIN, Sept. 20, 2022 /PRNewswire/ -- Methuselah Foundation, the original biomedical charity devoted to extending the human health span, announced a $1 million competition to encourage innovation that will enable medicine to move away from unreliable animal testing.

Key Points: 
  • Though medicine relies heavily on animal testing for the development of new drugs and therapies, it is unreliable, ineffective and costly.
  • Today, development of a new oncology drug can cost up to $5 billion and take up to 15 years.
  • Because it uses bioengineered human tissue, it promises to be a superior alternative to animal testing for research, clinical trials and precision medicine.
  • "I am excited to support this Animal Free Precision Medicine initiative and the incentives it creates to accelerate this new era of medical research."

Regenative Labs announces groundbreaking Wharton's Jelly research demonstrating HCT/P compliance after processing

Retrieved on: 
Monday, August 15, 2022

PENSACOLA, Fla., Aug. 15, 2022 /PRNewswire/ -- Regenative Labs, a leading HCT/P manufacturer, has co-authored a pioneering paper together with experts from The Institute of Regenative Medicine and the Department of Pharmacology and Chemical Biology, Baylor College of Medicine.

Key Points: 
  • Regenative Labs has pioneered the use of perinatal tissue allografts and is pleased that this paper supports our current homologous use practices, consistent with our 361 status.
  • About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient's conditions using Wharton's Jelly innovations rather than masking the pain with other treatments.
  • Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development.
  • Regenative Labs's expert product research and development team compliesFDA guidelines of minimal manipulation for homologous use.

MIMEDX Announces Collaborative Agreement with the Wake Forest Institute for Regenerative Medicine

Retrieved on: 
Thursday, May 6, 2021

b'MARIETTA, Ga., May 06, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (Nasdaq: MDXG) (\xe2\x80\x9cMIMEDX\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced a collaborative agreement with the Wake Forest Institute for Regenerative Medicine (WFIRM) to develop and advance scientific evidence in support of safe and effective clinical therapies.

Key Points: 
  • b'MARIETTA, Ga., May 06, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (Nasdaq: MDXG) (\xe2\x80\x9cMIMEDX\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced a collaborative agreement with the Wake Forest Institute for Regenerative Medicine (WFIRM) to develop and advance scientific evidence in support of safe and effective clinical therapies.
  • I am eager to work with Tim Wright and his management team, and applaud the transformational progress they have made to strategically position MIMEDX for the future.\xe2\x80\x9d\n\xe2\x80\x9cThe Wake Forest Institute for Regenerative Medicine is designed for collaboration,\xe2\x80\x9d added Robert Stein, M.D., Ph.D., MIMEDX Executive Vice President of Research and Development.
  • A number of the basic principles of tissue engineering and regenerative medicine were first developed at the institute.
  • The institute, which is part of Wake Forest School of Medicine, is located in the Innovation Quarter in downtown Winston-Salem, NC, and is driven by the urgent needs of patients.

Longeveron Selected to Present at the 2021 World Stem Cell Summit

Retrieved on: 
Tuesday, April 27, 2021

b'MIAMI, April 27, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announces it has been selected to present at the 2021 World Stem Cell Summit taking place virtually on June 14-18, in combination with the Wake Forest Institute for Regenerative Medicine (WFIRM) and Regenerative Medicine Foundation (RMF).\nDr.

Key Points: 
  • b'MIAMI, April 27, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announces it has been selected to present at the 2021 World Stem Cell Summit taking place virtually on June 14-18, in combination with the Wake Forest Institute for Regenerative Medicine (WFIRM) and Regenerative Medicine Foundation (RMF).\nDr.
  • Longeveron is also preparing for a Phase 2 Aging Frailty trial to initiate this year in Japan.
  • Lomecel-B is considered an investigational therapy in Japan, the US and The Bahamas.\nLongeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions.
  • Further information relating to factors that may impact the Company\'s results and forward-looking statements are disclosed in the Company\'s filings with the SEC.

Javara, Inc. and Wake Forest Baptist Health Launch an Innovative Partnership to Amplify Clinical Trial Access

Retrieved on: 
Wednesday, February 10, 2021

This agreement forms a unique and unparalleled relationship between the Wake Forest Baptist Health system and Javara's expert research team to ensure clinical research as a care option extends to patients across the 24 counties that Wake Forest Baptist serves.

Key Points: 
  • This agreement forms a unique and unparalleled relationship between the Wake Forest Baptist Health system and Javara's expert research team to ensure clinical research as a care option extends to patients across the 24 counties that Wake Forest Baptist serves.
  • The initial partnership with Wake Forest Baptist and the recent expansion of offerings would not have been possible without the recognition and support from Gregory L. Burke, M.D., chief science officer at Wake Forest Baptist.
  • Expanded clinical trial operations between Javara and Wake Forest Baptist are expected to begin in May 2021.
  • Wake Forest Baptist Health:Joe McCloskey, [email protected] , 336-716-1273
    Wake Forest Baptist Health( www.wakehealth.edu ) is a pre-eminent academic health system based in Winston-Salem, North Carolina.

Javara, Inc. and Wake Forest Baptist Health Launch and Innovative Partnership to Amplify Clinical Trail Access

Retrieved on: 
Wednesday, February 10, 2021

This agreement forms a unique and unparalleled relationship between the Wake Forest Baptist Health system and Javara's expert research team to ensure clinical research as a care option extends to patients across the 24 counties that Wake Forest Baptist serves.

Key Points: 
  • This agreement forms a unique and unparalleled relationship between the Wake Forest Baptist Health system and Javara's expert research team to ensure clinical research as a care option extends to patients across the 24 counties that Wake Forest Baptist serves.
  • The initial partnership with Wake Forest Baptist and the recent expansion of offerings would not have been possible without the recognition and support from Gregory L. Burke, M.D., chief science officer at Wake Forest Baptist.
  • Expanded clinical trial operations between Javara and Wake Forest Baptist are expected to begin in May 2021.
  • Wake Forest Baptist Health:Joe McCloskey, [email protected] , 336-716-1273
    Wake Forest Baptist Health( www.wakehealth.edu ) is a pre-eminent academic health system based in Winston-Salem, North Carolina.

Atrium Health and Wake Forest Baptist Health Combine, Create Next-Generation Academic Health System

Retrieved on: 
Friday, October 9, 2020

CHARLOTTE, N.C.,and WINSTON-SALEM, N.C., Oct. 9, 2020 /PRNewswire/ --A new era of healthcare was ushered in today as Atrium Health and Wake Forest Baptist Health, including Wake Forest School of Medicine, officially joined together as a single enterprise, Atrium Health.

Key Points: 
  • CHARLOTTE, N.C.,and WINSTON-SALEM, N.C., Oct. 9, 2020 /PRNewswire/ --A new era of healthcare was ushered in today as Atrium Health and Wake Forest Baptist Health, including Wake Forest School of Medicine, officially joined together as a single enterprise, Atrium Health.
  • Wake Forest Baptist Health and Wake Forest School of Medicine will become the academic core of Atrium Health, building a second campus of the school of medicine in Charlotte, which is currently the largest city in the U.S. without a 4-year medical school.
  • Freischlag has been named the chief academic officer for Atrium Health, in addition to her current role as CEO of Wake Forest Baptist Health and dean of Wake Forest School of Medicine.
  • Wake Forest Baptist Health ( www.wakehealth.edu )is a pre-eminent academic health system,with more than 20,000 employees,based in Winston-Salem, North Carolina.